Carpal Tunnel Syndrome Companies Strategic Expansion Initiatives, Revenue Diversification, Strategic Joint Ventures, Licensing and Monetization, Peer Comparison Analysis, Leadership and Governance

Carpal Tunnel Syndrome Manufacturers and Recent Developments

The global Carpal Tunnel Syndrome (CTS) market size is calculated at USD 977.57 million in 2024 and is expected to be worth USD 1,405.80 million by 2034, expanding at a CAGR of 3.7% from 2024 to 2034.

Carpal Tunnel Syndrome Market Companies

• GlaxoSmithKline Plc
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Novartis AG (Switzerland)
• Stryker Corporation
• Smith & Nephew Plc
• CONMED Corporation
• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company

Latest Announcements by Industry Leaders

Dr. Jeff Barwick, an orthopedic surgeon at ECU Health Beaufort Hospital, commented that the conventional surgery for carpal tunnel syndrome takes around two weeks to several months for patients to completely recover. However, the use of ultrasound technology provides the same treatment efficacy but with a minimal incision. This enhances the healing process in patients and aids in a better quality of life.

Recent Developments in the Carpal Tunnel Syndrome Market

• In December 2023, researchers from the Indian Institute of Science (IISc), Bengaluru, developed an AI tool to detect carpal tunnel syndrome using ultrasound videos that identify the median nerve.
• In September 2023, Sonex Health, Inc., an Eagen-based company, announced that it had raised $40 million in Series B funding. Funding was raised to increase patient access to Sonex’s device, which was developed to treat carpal tunnel syndrome faster and with less recovery time.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com